WO2006099169A3 - Novel liposome compositions - Google Patents

Novel liposome compositions Download PDF

Info

Publication number
WO2006099169A3
WO2006099169A3 PCT/US2006/008650 US2006008650W WO2006099169A3 WO 2006099169 A3 WO2006099169 A3 WO 2006099169A3 US 2006008650 W US2006008650 W US 2006008650W WO 2006099169 A3 WO2006099169 A3 WO 2006099169A3
Authority
WO
WIPO (PCT)
Prior art keywords
liposome compositions
novel liposome
containing compositions
lipid
targeted liposomes
Prior art date
Application number
PCT/US2006/008650
Other languages
French (fr)
Other versions
WO2006099169A2 (en
Inventor
Kazushi Okada
Tadayuki Ibuki
Donghyun Kim
Tadashi Fujisawa
Original Assignee
Mebiopharm Co Ltd
Kazushi Okada
Tadayuki Ibuki
Donghyun Kim
Tadashi Fujisawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2006223329A priority Critical patent/AU2006223329B2/en
Priority to DK06737793.7T priority patent/DK1863448T3/en
Priority to MX2007010996A priority patent/MX2007010996A/en
Priority to PL06737793T priority patent/PL1863448T3/en
Priority to BRPI0608297-1A priority patent/BRPI0608297A2/en
Priority to KR1020077023219A priority patent/KR101352490B1/en
Priority to SI200631892T priority patent/SI1863448T1/en
Priority to JP2008500977A priority patent/JP5438317B2/en
Application filed by Mebiopharm Co Ltd, Kazushi Okada, Tadayuki Ibuki, Donghyun Kim, Tadashi Fujisawa filed Critical Mebiopharm Co Ltd
Priority to CN2006800159670A priority patent/CN101170995B/en
Priority to CA002600446A priority patent/CA2600446A1/en
Priority to NZ561569A priority patent/NZ561569A/en
Priority to EP06737793.7A priority patent/EP1863448B1/en
Priority to ES06737793.7T priority patent/ES2529453T3/en
Publication of WO2006099169A2 publication Critical patent/WO2006099169A2/en
Publication of WO2006099169A3 publication Critical patent/WO2006099169A3/en
Priority to NO20075136A priority patent/NO20075136L/en
Priority to HK08105936.8A priority patent/HK1111625A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure provides lipid-containing compositions, including targeted liposomes encapsulating drug, and pharmaceutical formulations thereof, as well as methods for the making and using the lipid-containing compositions, including the use of the targeted liposomes in the treatment of cancer and other diseases.
PCT/US2006/008650 2005-03-10 2006-03-08 Novel liposome compositions WO2006099169A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN2006800159670A CN101170995B (en) 2005-03-10 2006-03-08 Novel liposome compositions
DK06737793.7T DK1863448T3 (en) 2005-03-10 2006-03-08 NEW LIPOSOM COMPOSITIONS
CA002600446A CA2600446A1 (en) 2005-03-10 2006-03-08 Novel liposome compositions
BRPI0608297-1A BRPI0608297A2 (en) 2005-03-10 2006-03-08 liposome compositions
KR1020077023219A KR101352490B1 (en) 2005-03-10 2006-03-08 Novel liposome compositions
SI200631892T SI1863448T1 (en) 2005-03-10 2006-03-08 Novel liposome compositions
JP2008500977A JP5438317B2 (en) 2005-03-10 2006-03-08 Novel liposome composition
AU2006223329A AU2006223329B2 (en) 2005-03-10 2006-03-08 Novel liposome compositions
MX2007010996A MX2007010996A (en) 2005-03-10 2006-03-08 Novel liposome compositions.
PL06737793T PL1863448T3 (en) 2005-03-10 2006-03-08 Novel liposome compositions
NZ561569A NZ561569A (en) 2005-03-10 2006-03-08 Novel liposome compositions comprising SuccNomegaPE:NomegaPE:additional lipids and TF-NomegaPE:NomegaPE:additional lipids
EP06737793.7A EP1863448B1 (en) 2005-03-10 2006-03-08 Novel liposome compositions
ES06737793.7T ES2529453T3 (en) 2005-03-10 2006-03-08 New liposome compositions
NO20075136A NO20075136L (en) 2005-03-10 2007-10-09 New liposome preparations
HK08105936.8A HK1111625A1 (en) 2005-03-10 2008-05-28 Novel liposome compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005067469A JP2006248978A (en) 2005-03-10 2005-03-10 New liposome preparation
JP2005-67469 2005-03-10

Publications (2)

Publication Number Publication Date
WO2006099169A2 WO2006099169A2 (en) 2006-09-21
WO2006099169A3 true WO2006099169A3 (en) 2007-02-22

Family

ID=36992280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/008650 WO2006099169A2 (en) 2005-03-10 2006-03-08 Novel liposome compositions

Country Status (22)

Country Link
US (3) US7829113B2 (en)
EP (1) EP1863448B1 (en)
JP (2) JP2006248978A (en)
KR (1) KR101352490B1 (en)
CN (1) CN101170995B (en)
AU (1) AU2006223329B2 (en)
BR (1) BRPI0608297A2 (en)
CA (1) CA2600446A1 (en)
CY (1) CY1116075T1 (en)
DK (1) DK1863448T3 (en)
ES (1) ES2529453T3 (en)
HK (1) HK1111625A1 (en)
HU (1) HUE024290T2 (en)
MX (1) MX2007010996A (en)
NO (1) NO20075136L (en)
NZ (1) NZ561569A (en)
PL (1) PL1863448T3 (en)
PT (1) PT1863448E (en)
RU (1) RU2454229C2 (en)
SI (1) SI1863448T1 (en)
WO (1) WO2006099169A2 (en)
ZA (1) ZA200708600B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829113B2 (en) 2005-03-10 2010-11-09 Mebiopharm Co., Ltd. Liposome compositions

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462825B1 (en) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 Liposomes useful for drug delivery
CN101209243B (en) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament and preparation thereof
US20120003294A1 (en) * 2007-08-17 2012-01-05 Celator Pharmaceuticals, Inc. Fixed ratio camptothecens/platinum agents
WO2009036059A2 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel stat3 pathway inhibitors and cancer stem cell inhibitors
TWI468188B (en) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
JP5854559B2 (en) * 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド Method for preparing vesicles and preparations produced therefrom
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US8591942B2 (en) 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
WO2011116399A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
WO2011128896A1 (en) * 2010-04-12 2011-10-20 Ramot At Tel-Aviv University Ltd. Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders
JP5909745B2 (en) 2010-11-12 2016-04-27 クール ファーマシューティカルズ ディベロップメント カンパニー Drugs for inflammatory diseases as well as drugs for viral or bacterial infections
WO2012153616A1 (en) * 2011-05-10 2012-11-15 国立大学法人北海道大学 Lipid membrane structure capable of imigrating to target cell and method for producing same, and method for screening for substance exhibiting effect thereof in target cell
WO2013011598A1 (en) * 2011-07-15 2013-01-24 コニカミノルタホールディングス株式会社 Liposome-containing preparation utilizing dissolution aid, and method for producing same
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
CN104080480A (en) * 2012-01-01 2014-10-01 奇比艾企业有限公司 Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013278056B2 (en) 2012-06-21 2018-07-05 Northwestern University Peptide conjugated particles
ES2733061T3 (en) 2012-08-10 2019-11-27 Taiho Pharmaceutical Co Ltd Aqueous dispersion of stable oxaliplatin encapsulating liposomes and method for stabilization thereof
CA2894846A1 (en) 2012-12-12 2014-06-19 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of cancer
CN103083239B (en) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 A kind of bufalin liposome and its preparation method and application
TW201427681A (en) 2013-01-07 2014-07-16 Superlab Far East Ltd A method for treating tumor by using recombinant interferon with changed spatial configuration
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR20160014584A (en) 2013-03-13 2016-02-11 코어 파마슈티칼스 디벨롭먼트 컴퍼니 Immune-modifying particles for the treatment of inflammation
MX2015012199A (en) * 2013-03-13 2015-11-30 Mallinckrodt Llc Liposomal cisplatin compositions for cancer therapy.
MX2015012200A (en) * 2013-03-13 2015-11-30 Mallinckrodt Llc Liposome oxaliplatin compositions for cancer therapy.
BR112015025347A2 (en) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
ES2762187T3 (en) 2013-08-13 2020-05-22 Univ Northwestern Peptide-conjugated particles
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
DK3066201T3 (en) 2013-11-07 2018-06-06 Editas Medicine Inc CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
US20170007700A1 (en) * 2014-02-21 2017-01-12 The Curators Of The University Of Missouri Compositions and methods for boron neutron capture therapy
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
EP3212165B1 (en) 2014-10-30 2024-02-28 President and Fellows of Harvard College Delivery of negatively charged proteins using cationic lipids
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP6797116B2 (en) 2015-06-24 2020-12-09 日本化薬株式会社 New platinum (IV) complex
RU2760185C2 (en) 2015-08-20 2021-11-22 Ипсен Биофарм Лтд. Combination therapy using liposomal irinotecan and parp inhibitor for the treatment of cancer
WO2017034957A1 (en) 2015-08-21 2017-03-02 Merrimack Pharmaceuticals, Inc. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
BR112018003530A2 (en) 2015-09-14 2018-09-25 Nippon Kayaku Kabushiki Kaisha At least 6 Distribution are the polymers joint objects of a platinum complex.
EP3362049A1 (en) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
JP7109784B2 (en) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ Evolved Cas9 protein for gene editing
WO2017087685A1 (en) * 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
KR20180099734A (en) 2015-12-22 2018-09-05 니폰 가야꾸 가부시끼가이샤 Polymer conjugate of platinum (II) complex with sulfoxide derivative
CN110590855B (en) 2016-01-25 2023-05-12 沈阳药科大学 Preparation method of platinum complex, liposome containing platinum complex and preparation method of liposome
CN117757795A (en) 2016-03-07 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) Micrornas and methods of use thereof
WO2017179614A1 (en) * 2016-04-15 2017-10-19 富士フイルム株式会社 Microneedle array
CN109562067A (en) * 2016-08-02 2019-04-02 库里尔克思股份有限公司 The method for preparing liposome
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
KR20230145501A (en) 2016-08-12 2023-10-17 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. Polyglutamated antifolates and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
SG10201912338RA (en) 2016-11-02 2020-02-27 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
CN109996809A (en) 2016-11-14 2019-07-09 诺华股份有限公司 Composition relevant to fusogenic protein MINION, method and therapeutical uses
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (en) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cytosine to Guanine Base Editing Agent
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
CA3063395A1 (en) * 2017-05-12 2018-11-15 Curinanorx, Llc Methods for the preparation of liposomes comprising drugs
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP2020520923A (en) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド Methods for treating cancer
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
WO2019157138A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
CA3090387A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CN108524450A (en) * 2018-04-16 2018-09-14 温州医科大学 Oxaliplatin and MDC1-AS based on magnetic temperature-sensitive cationic-liposome transmit the preparation and application of pharmaceutical carrier altogether
MX2021003663A (en) 2018-09-28 2021-05-28 Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration.
BR112021006539A2 (en) 2018-10-09 2021-07-06 Univ British Columbia compositions and competent systems of vesicles competent for transfection free of organic solvents and detergents and related methods
MX2021011426A (en) 2019-03-19 2022-03-11 Broad Inst Inc Methods and compositions for editing nucleotide sequences.
CN111721841B (en) * 2019-03-19 2022-07-12 海南长安国际制药有限公司 Detection of lobaplatin-related substances
CN110292563B (en) * 2019-06-12 2021-07-16 兰州大学 Method for inducing cancer cell apoptosis by using folic acid heat-sensitive liposome-based anion carrier
CA3174286A1 (en) 2020-04-02 2021-10-07 Robert PLACE Targeted inhibition using engineered oligonucleotides
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN112129871B (en) * 2020-09-04 2021-06-15 斯微(上海)生物科技有限公司 Method for detecting contents of DOPE and M5 phospholipids in composite phospholipid liposome
CN112870164B (en) * 2021-01-25 2021-12-17 山东大学 Double-targeting drug-loaded liposome and preparation method and application thereof
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004232A1 (en) * 1985-01-18 1986-07-31 Cooper-Lipotech, Inc. Liposome composition and method
US5419914A (en) * 1990-10-09 1995-05-30 Vestar, Inc. Phospholipid analogue vesicle
WO1996021658A1 (en) * 1995-01-09 1996-07-18 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5891468A (en) * 1996-10-11 1999-04-06 Sequus Pharmaceuticals, Inc. Fusogenic liposome compositions and method
EP1209469A1 (en) * 2000-11-22 2002-05-29 Vectron Therapeutics AG Production and use of a targeted diagnostic system
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (en) 1976-09-06 1985-09-13 喜徳 喜谷 Cis platinum(2) complex of 1,2-diaminocyclohexane isomer
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GR75598B (en) 1980-04-29 1984-08-01 Sanofi Sa
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4925661A (en) * 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US5026651A (en) * 1985-04-25 1991-06-25 Board Of Regents, The University Of Texas System Methods and compositions for the production of human transferrin
US4983397A (en) * 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US5384127A (en) * 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
JPH0714865B2 (en) * 1986-10-28 1995-02-22 武田薬品工業株式会社 Liposome preparation and method for producing the same
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
FR2631826B1 (en) * 1988-05-27 1992-06-19 Centre Nat Rech Scient PARTICULATE VECTOR USEFUL IN PARTICULAR FOR THE TRANSPORT OF BIOLOGICALLY ACTIVATED MOLECULES AND METHOD FOR THE PREPARATION THEREOF
JPH0720857B2 (en) 1988-08-11 1995-03-08 テルモ株式会社 Liposome and its manufacturing method
US5474772A (en) * 1989-08-02 1995-12-12 Cobe Laboratories, Inc. Method of treatment with medical agents
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US6509032B1 (en) 1991-08-28 2003-01-21 Mcmaster University Cationic amphiphiles
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
JPH0776230B2 (en) * 1992-01-13 1995-08-16 田中貴金属工業株式会社 Method for producing platinum compound
JPH06287021A (en) * 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk Optical resolution of optically active platinum complex compound
JP2673331B2 (en) * 1993-01-12 1997-11-05 田中貴金属工業 株式会社 Optically pure cis-oxalate (trans-1-1,2-cyclohexanediamine) platinum (▲ II ▼)
US20030190638A1 (en) 1992-05-13 2003-10-09 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US20030100489A1 (en) * 1992-10-16 2003-05-29 Beach David H. Cell-cycle regulatory proteins, and uses related thereto
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
JP3025602B2 (en) 1993-05-21 2000-03-27 デビオファーム エス．アー． Method for producing optically high purity cis-oxalate (trans-l-l, 2-cyclohexanediamine) platinum (II) complex
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
CN1206982C (en) * 1993-10-06 2005-06-22 安姆根有限公司 Stable protein: phospholipid compositions and methods
EP0734438A4 (en) * 1993-12-17 1998-12-23 Spinal Cord Society Method for inducing dna synthesis in neurons
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
JP3590983B2 (en) * 1994-03-04 2004-11-17 日本油脂株式会社 Phospholipid derivatives
ZA952485B (en) 1994-03-28 1995-12-15 Nycomed Imaging As Liposomes
WO1996004232A1 (en) 1994-07-29 1996-02-15 Abbott Laboratories Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane
DE69519300T2 (en) 1994-08-08 2001-05-31 Debiopharm Sa STABLE MEDICINAL PRODUCT CONTAINING OXALIPLATINE
ATE198419T1 (en) * 1994-10-14 2001-01-15 Liposome Co Inc ETHERLIPID LIPOSOMES AND THEIR THERAPEUTIC USE
EP0715854B1 (en) 1994-11-11 2003-09-10 Debiopharm S.A. Carcinostatic compositions containing cis-oxaliplatinum and one or more other compatible carcinostatic substances
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
TW319763B (en) 1995-02-01 1997-11-11 Epix Medical Inc
US5780052A (en) * 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
US5834012A (en) 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US20020022264A1 (en) 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JPH09278785A (en) 1996-04-10 1997-10-28 Tanaka Kikinzoku Kogyo Kk Production of platinum compound
FR2740686B1 (en) 1995-11-03 1998-01-16 Sanofi Sa STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION
US6428977B1 (en) 1995-12-20 2002-08-06 Curis, Inc. Signalin family of TGFβ signal transduction proteins, and uses related thereto
JP3735921B2 (en) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 GPIb / lipid complex and uses thereof
AU2112697A (en) * 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
US6153646A (en) 1996-03-11 2000-11-28 Yoshinori Kidani Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes
WO1997035561A1 (en) * 1996-03-28 1997-10-02 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions
JP3154399B2 (en) 1996-07-04 2001-04-09 デビオファーム エス．アー． Method for producing platinum compound
WO1997042166A1 (en) * 1996-05-02 1997-11-13 Terumo Kabushiki Kaisha Amidine derivatives and drug carriers comprising them
ES2208946T3 (en) * 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. LIPOSOMES CONTAINING A CISPLATIN COMPOUND.
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU725257B2 (en) * 1996-10-15 2000-10-12 Transave, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US6087325A (en) * 1996-10-15 2000-07-11 The Liposome Company, Inc. Peptide-lipid conjugates
WO1998027209A1 (en) 1996-12-18 1998-06-25 Emory University Polycationic oligomers
WO1998039009A1 (en) * 1997-03-07 1998-09-11 Sanofi Pharmaceuticals, Inc. Method of treating a tumor
DE19709704C2 (en) * 1997-03-10 1999-11-04 Michael Georgieff Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia
JPH10253632A (en) * 1997-03-10 1998-09-25 Nissui Pharm Co Ltd Method, kit and device for analysis
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
US6272370B1 (en) * 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
WO1998059035A2 (en) 1997-06-25 1998-12-30 The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health Serum-free cell growth medium
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
IL134985A0 (en) * 1997-10-02 2001-05-20 Epix Medical Inc A method for contrast enhanced diagnostic imaging
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
WO1999041403A1 (en) * 1998-02-12 1999-08-19 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6245427B1 (en) * 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
ES2178474T3 (en) * 1998-10-14 2002-12-16 Debiopharm Sa CONDITIONING OF A PREPARATION OF OXALIPLATIN.
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
JP2003502025A (en) 1999-05-17 2003-01-21 エイブイアイ バイオファーマ， インコーポレイテッド Combination approach for treatment of cancer with hcG vaccine
JP2001002592A (en) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd Composition for gene-transducing
US6280054B1 (en) * 1999-07-02 2001-08-28 Zight Corporation Image generator having an improved illumination system
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
WO2001011826A1 (en) * 1999-08-09 2001-02-15 Fujitsu Limited Package control device and method
PT1207875E (en) 1999-08-30 2004-02-27 Debiopharm Sa PHARMACEUTICAL PREPARATION OF OXALIPLATIN STABILIZER FOR ADMINISTRATION
CN1433478A (en) 1999-12-30 2003-07-30 诺瓦提斯公司 Novel colloid synthetic vectors for gene therapy
WO2001049266A2 (en) 1999-12-30 2001-07-12 Gwathemy Judith K Iron chelator delivery system
WO2001051003A2 (en) * 2000-01-10 2001-07-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
ES2291295T3 (en) * 2000-03-02 2008-03-01 Mitsubishi Pharma Corporation CONSTRUCTION WITH GPIB-LIPIDO LINK AND ITS USE.
JP4449147B2 (en) 2000-03-22 2010-04-14 日油株式会社 Method for producing phosphatidylethanolamine derivative
FR2806727A1 (en) 2000-03-23 2001-09-28 Pf Medicament MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING IN THE N-TERMINAL END A GLUTAMIC ACID OR GLUTAMINE IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALT
EP1272160B1 (en) 2000-04-12 2007-01-17 Liplasome Pharma A/S Lipid-based drug delivery systems for topical application
JP2004511426A (en) * 2000-05-03 2004-04-15 ミュンヘン　バイオテク　アーゲー Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
JP2004508385A (en) * 2000-09-11 2004-03-18 インスティチュート・パスツール Mechanism of mitochondrial membrane permeabilization by HIV-1 VPR, a mimic of Vpr, and method for screening for active molecules capable of altering and / or preventing and / or mimicking the interaction between VPR and ANT
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
EP1324758B1 (en) 2000-10-03 2005-01-12 Debiopharm S.A. Plga/pla-type polymer microspheres encapsulating a water-soluble substance and process thereof
AU2002223013A1 (en) * 2000-12-12 2002-06-24 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
EP1342063A4 (en) * 2000-12-12 2004-07-14 Australian Inst Marine Science Assay for paralytic shellfish toxin
US6897196B1 (en) * 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6703524B2 (en) * 2001-02-20 2004-03-09 Lkt Laboratories, Inc. Organoselenium compounds for cancer chemoprevention
EP1368022B1 (en) 2001-03-02 2007-06-20 Debiopharm S.A. Use of a vial containing an oxaliplatinum solution
FI113840B (en) 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Use of matrix metalloproteinase inhibitors in targeting liposomes
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
US20030203865A1 (en) 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
US20030082228A1 (en) * 2001-05-09 2003-05-01 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US20030108986A1 (en) * 2001-06-21 2003-06-12 Euroscreen, S.A. Compositions and methods comprising G-protein coupled receptors
WO2003004505A1 (en) 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
EP1424898A4 (en) * 2001-08-20 2008-04-02 Transave Inc Treatment of cancers by inhalation of stable platinum-containing formulations
DE10144252A1 (en) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanoparticles with biologically active TNF immobilized on them
WO2003028640A2 (en) * 2001-10-03 2003-04-10 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
US7101985B2 (en) 2001-11-20 2006-09-05 Baylor College Of Medicine Methods and compositions in checkpoint signaling
JP4468617B2 (en) 2001-12-04 2010-05-26 デビオファーム エス．アー． Method for concomitant administration of anticancer agents and anticancer agents that can be used in combination
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
WO2003057730A1 (en) 2002-01-07 2003-07-17 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
US7282567B2 (en) * 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
EP1587944A4 (en) * 2002-03-01 2007-03-21 Dyax Corp Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
EP2865688A1 (en) * 2002-03-01 2015-04-29 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
WO2003082907A1 (en) 2002-03-29 2003-10-09 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
JP3415131B1 (en) * 2002-06-03 2003-06-09 メビオファーム株式会社 Liposome preparation
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
FR2840236B1 (en) 2002-06-03 2005-02-04 Inst Francais Du Petrole ZEOLITHIC MEMBRANE OF LOW THICKNESS, ITS PREPARATION AND USE IN SEPARATION
JP2005530817A (en) * 2002-06-07 2005-10-13 イミューノメディクス、インコーポレイテッド Neutrophil imaging in cystic fibrosis
US7238786B2 (en) * 2002-06-14 2007-07-03 Immunomedics, Inc. Monoclonal antibody cPAM4
US6790632B2 (en) 2002-06-17 2004-09-14 Stephen Eliot Zweig Membrane receptor reagent and assay
WO2004002453A1 (en) * 2002-06-28 2004-01-08 Protiva Biotherapeutics Ltd. Method and apparatus for producing liposomes
EP1546203B1 (en) 2002-08-01 2012-06-20 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040132652A1 (en) * 2002-08-30 2004-07-08 Shire Biochem Inc. Pharmaceutical compositions
EP1572104A4 (en) 2002-11-14 2007-01-17 Kirk Sperber Induction of apoptosis by hiv-1 infected monocytic cells
US20060141019A1 (en) 2002-11-15 2006-06-29 Toshiya Kai Liposome
AU2003277641B2 (en) 2003-02-17 2009-09-17 Mebiopharm Co., Ltd. Remedy for cancer
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
EP1633773A4 (en) * 2003-06-13 2010-10-20 Immunomedics Inc D-amino acid peptides
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
JP2005154282A (en) 2003-11-20 2005-06-16 Mebiopharm Co Ltd Method for producing gas-sealed liposome
US7582430B2 (en) * 2004-01-20 2009-09-01 United States Of America As Represented By The Secretary Of The Army Immunoliposome-nucleic acid amplification (ILNAA) assay
US7212869B2 (en) * 2004-02-04 2007-05-01 Medtronic, Inc. Lead retention means
CN1679957B (en) 2004-03-15 2010-06-09 尼普洛株式会社 A pharmaceutical composition containing liposomes for treating a cancer
JP2006248978A (en) 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
JP5345792B2 (en) 2008-02-19 2013-11-20 テイ・エス テック株式会社 Vehicle storage seat
JP5331648B2 (en) 2009-10-22 2013-10-30 株式会社日立製作所 How to modify a pulverized coal boiler

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004232A1 (en) * 1985-01-18 1986-07-31 Cooper-Lipotech, Inc. Liposome composition and method
US5419914A (en) * 1990-10-09 1995-05-30 Vestar, Inc. Phospholipid analogue vesicle
WO1996021658A1 (en) * 1995-01-09 1996-07-18 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5891468A (en) * 1996-10-11 1999-04-06 Sequus Pharmaceuticals, Inc. Fusogenic liposome compositions and method
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
EP1209469A1 (en) * 2000-11-22 2002-05-29 Vectron Therapeutics AG Production and use of a targeted diagnostic system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARUYAMA K ET AL: "Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT)", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 98, no. 2, 11 August 2004 (2004-08-11), pages 195 - 207, XP004521710, ISSN: 0168-3659 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829113B2 (en) 2005-03-10 2010-11-09 Mebiopharm Co., Ltd. Liposome compositions
US8758810B2 (en) 2005-03-10 2014-06-24 Mebiopharm Co., Ltd. Liposome compositions

Also Published As

Publication number Publication date
AU2006223329B2 (en) 2011-11-17
DK1863448T3 (en) 2015-02-16
AU2006223329A1 (en) 2006-09-21
PL1863448T3 (en) 2015-05-29
US20110081404A1 (en) 2011-04-07
US20140363491A1 (en) 2014-12-11
RU2007137492A (en) 2009-04-20
CN101170995A (en) 2008-04-30
CY1116075T1 (en) 2017-02-08
BRPI0608297A2 (en) 2009-12-08
ES2529453T3 (en) 2015-02-20
US20060222696A1 (en) 2006-10-05
JP2006248978A (en) 2006-09-21
WO2006099169A2 (en) 2006-09-21
PT1863448E (en) 2015-02-10
EP1863448A2 (en) 2007-12-12
NO20075136L (en) 2007-12-07
SI1863448T1 (en) 2015-03-31
US7829113B2 (en) 2010-11-09
MX2007010996A (en) 2007-11-07
RU2454229C2 (en) 2012-06-27
JP2008538105A (en) 2008-10-09
HUE024290T2 (en) 2016-01-28
HK1111625A1 (en) 2008-08-15
KR101352490B1 (en) 2014-02-04
EP1863448B1 (en) 2014-11-26
CA2600446A1 (en) 2006-09-21
NZ561569A (en) 2011-03-31
US8758810B2 (en) 2014-06-24
ZA200708600B (en) 2009-01-28
KR20080002819A (en) 2008-01-04
CN101170995B (en) 2013-01-16
JP5438317B2 (en) 2014-03-12

Similar Documents

Publication Publication Date Title
WO2006099169A3 (en) Novel liposome compositions
WO2008030818A3 (en) Novel liposome compositions
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
CL2007002513A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED ISOINDOLIN, INTERMEDIATE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND PREVENTION OF DISEASES SUCH AS CANCER, PAIN, MACULAR DEGENERATION, AMONG OTHERS.
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
MY143795A (en) Tetrahydropyridoindole derivatives
CL2007002708A1 (en) COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRIDINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, CAQUEXY, INFLAMMATORY DISORDERS, AMONG OTHERS.
TW200716646A (en) (S)-N-methylnaltrexone
MX2009006704A (en) New compounds.
WO2006052767A3 (en) Compositions and methods for stabilizing liposomal camptothecin formulations
WO2007064857A3 (en) Amphoteric liposome formulation
MXPA05011208A (en) Topical formulation of ivermectin for the treatment of dermatological conditions.
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
IL226313A0 (en) A method for producing gamma-carboxylated human prothrombin isolated prothrombin produced by such method, pharmaceutical composition comprising it and use thereof as medicaments and in the manufacture of medicaments for coagulation therapy
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2006055352A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2008063808A3 (en) Encapsulated peptide amphiphile nanostructures
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
CL2008000495A1 (en) Compounds derived from tetrahydro-pyrazolo [4,3-c] pyridine; pharmaceutical composition; and use in the treatment of diseases such as allergies, inflammation, pain, cancer, among others.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680015967.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2600446

Country of ref document: CA

Ref document number: 2008500977

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010996

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3440/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 561569

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006223329

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006737793

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007137492

Country of ref document: RU

Ref document number: 1020077023219

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006223329

Country of ref document: AU

Date of ref document: 20060308

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0608297

Country of ref document: BR

Kind code of ref document: A2